Daiichi Offer For Ranbaxy Oversubscribed, Canadians Make Demands
This article was originally published in PharmAsia News
Japan's Daiichi Sankyo plans to give back some of the shares it bought in India's Ranbaxy Laboratories after learning the tender offer for another 20 percent stake was oversubscribed. The firms, still awaiting Indian government approval for the merger, also were hit by a Canadian government demand that Ranbaxy's Canadian division report on how it plans to respond to a U.S. FDA ban on 30 of its generic drugs. Daiichi already has purchased the shares of Ranbaxy's founding family to give it an additional 34.8 percent share, and the other investors tendered more than 92.5 million shares during the tender offer. (Click here for more
You may also be interested in...
The Environmental Working Group and Scientific Analytical Institute say inadequate testing of talc-containing personal-care products is to blame for findings of asbestos in cosmetics, including three of 21 powder-based cosmetics SAI analyzed at EWG’s request. They continue to push for updated testing standards that include electron microscopy as a core component.
Can Atlas Biomed unlock Japan's self-care market with its direct-to-consumer DNA and microbiome tests? HBW Insight catches up with the company's co-founder and CEO to discuss this and also how Atlas has been driving its European expansion plans despite coronavirus.
France's ANSES warns women using oral contraceptives not to use a supplement marketed by UK firm Hairburst after linking the product's consumption to two cases of severe acute hepatitis.